ArticleMolecular biotechnology2026
Surface-Functionalization of PP7 Virus-Like Particles with Spytag for Bioconjugation Applications.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Virus-like particles (VLPs) are protein-based nanoscale assemblies derived from structural proteins of viruses. They are non-infectious scaffolds and are highly immunogenic; thus, they widely used as scaffolds to display and enhance the immunogenicity of less immunogenic foreign antigens. Different approaches, including genetic insertions, can be used to display foreign antigens on VLPs; however, some of these approaches have limitations, i.e., inability of viral coat proteins to tolerate a foreign insertion. In this study, we assessed the tolerability of bacteriophage Qβ and PP7 coat proteins to insertions of Spytag003 or Spytag peptides; we assessed whether the insertions of these peptides to the coat proteins will affect the ability of the recombinant coat proteins to assemble into VLPs; chimeric VLPs displaying these peptides can be used to conjugate antigens for vaccine studies. While the insertion of Spytag003 peptide at either the N or C termini of the coat protein of Qβ and at the C terminus of the coat protein of PP7 did not affect the expression of the recombinant proteins, the expressed proteins were not soluble. In contrast, insertion of the shorter Spytag at either the N terminus or AB-loop of PP7 gave rise to soluble proteins that assembled into VLPs. PP7-Spytag VLPs were successfully conjugated with SpyCatcher003 and a fungal antigen. Immunization studies revealed that Spycatcher003 protein conjugated on PP7-SpyTag VLPs elicited significantly higher anti-Spycatcher003 antibody titers compared to unconjugated Spycatcher003 (p = 0.0286). Together, these findings establish proof of concept that PP7-Spytag VLPs should be explored as a platform to conjugate foreign proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.